The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of oral cyclophosphamide on the immunogenicity of DPX-Survivac in ovarian cancer patients: Results of a phase I study.
Neil Lorne Berinstein
Consultant or Advisory Role - Immunovaccine
Other Remuneration - Immunovaccine
Amit M. Oza
No relevant relationships to disclose
Kunle Odunsi
No relevant relationships to disclose
Mohan Karkada
Employment or Leadership Position - Immunovaccine
Jeannine A Villella
No relevant relationships to disclose
John J. Nemunaitis
No relevant relationships to disclose
Michael Morse
No relevant relationships to disclose
Tanja Pejovic
No relevant relationships to disclose
James Bentley
No relevant relationships to disclose
Rita Nigam
Employment or Leadership Position - Immunovaccine
Genevieve Weir
Employment or Leadership Position - Immunovaccine
Lisa MacDonald
Employment or Leadership Position - Immunovaccine
Marianne Stanford
Employment or Leadership Position - Immunovaccine
Tomasz Burzykowski
Consultant or Advisory Role - Immunovaccine
Marc Mansour
Employment or Leadership Position - Immunovaccine
Stock Ownership - Immunovaccine